Long-Acting Male Contraceptive Shows Efficacy Beyond Two Years According to Biotech Firm
The Evolution of Masculine Contraception:
In the realm of birth control, the menu has primarily catered to women. But innovative biotech company, Contraline, is shaking things up with their groundbreaking, non-hormonal male contraceptive, ADAM, reportedly reaching a significant milestone in its clinical trials.
In a bold declaration, Contraline announced that ADAM, their revolutionary water-soluble hydrogel, has demonstrated effectiveness and safety over a two-year period during its initial human trial. Although the clinical results are yet to be published in a scientific journal, they plan to unveil more data during the American Urological Association (AUA) meeting on April 26.
The ADAM implant, injected into the vasa deferentia (the tubes transporting sperm from testicles to urethra) via a minor procedure, obstructs sperm while allowing for normal ejaculation. Pitching it as a promising alternative to condoms and vasectomies, Contraline envisions ADAM as a long-term, reversible contraceptive solution for men and couples.
Alexander Pastuszak, Contraline's Chief Medical Officer, shared, "Our mission was to create a male contraceptive option lasting two years, directly addressing consumer needs. These findings confirm that ADAM can achieve the intended lifespan. We remain confident about its safety, efficacy, and reversibility and see its potential to bestow men and couples with greater reproductive control."
ADAM's efficacy is illustrated by two participants in the first human trial achieving azoospermia (no sperm in their ejaculate) at the 24-month mark. In an earlier announcement, Contraline reported a 99.8% to 100.0% reduction in the count of moving sperm within 30 days of implantation.
These findings, as expressed by Kevin Eisenfrats, co-founder and CEO of Contraline, bring us a step closer to revolutionizing the contraceptive landscape, suggesting that ADAM may potentially match the efficiency of long-acting female contraceptives such as IUDs. IUDs, small devices inserted into the uterus, are prevalent among female contraceptive options.
Despite the encouraging results, Contraline's ADAM hasn't faced public data confirming its reversibility, nor do researchers know the long-term effects of blocking the vasa deferentia. Jon Oatley, a professor at Washington State University's School of Molecular Biosciences, highlighted these points to The Guardian, also advocating for a contraceptive pill or patch as a preferred option among most men.
Data from 2017 to 2019 shows that nearly 10% of women between 15 and 49 opted for long-acting reversible contraceptives like IUDs or implants requiring procedures, slightly trailing behind the pill's 14% usage rate. However, if ADAM proves to be safe and effective, it could potentially witness a sizable number of men opting for the long-term efficacy of an injection over the short-term benefits of other contraceptives.
- The science community is witnessing an evolution in contraceptive technology as biotech company Contraline develops a groundbreaking, non-hormonal male contraceptive named ADAM.
- Alexander Pastuszak, Contraline's Chief Medical Officer, confirmed that ADAM, a water-soluble hydrogel, has demonstrated effectiveness and safety over a two-year period during its initial human trial.
- The future of men's health-and-wellness, sexual-health, and mens-health could be reshaped with the adoption of ADAM, as it offers a long-term, reversible contraceptive solution.
- Gizmodo reported that the ADAM implant, injected into the vasa deferentia, obstructs sperm while allowing for normal ejaculation, presenting a potential alternative to condoms and vasectomies.
- Contraline envisions ADAM as a promising contraceptive option for men and couples, with the goal of addressing consumer needs and providing greater reproductive control.
- The regulatory bodies will have a crucial role in evaluating the safety, efficacy, and reversibility of ADAM, as well as understanding its long-term effects on urological health.
- As ADAM moves closer to market, it may challenge the popularity of existing female contraceptives like IUDs, with a potential shift towards long-acting, reversible contraceptives for both men and women in the world of health and wellness.
